Oruka Therapeutics (ORKA) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications.

• Lead programs target IL-23 (ORKA-001), IL-17A/F (ORKA-002), and TL1A (ORKA-004), aiming to improve efficacy and dosing over standard-of-care.

• Strategy leverages antibody engineering and format innovations to validated mechanisms, focusing on large markets with unmet need.

• Originated from a merger with a preclinical biotech and rebranded in August 2024.

Financial performance and metrics

• As of June 30, 2026: 61,069,887 shares of common stock and 137,138 shares of Series B Preferred Stock outstanding.

• Historical net tangible book value as of June 30, 2026 was $1,114.5 million, or $18.25 per share.

• After a $500 million offering at $104.86/share, as adjusted net tangible book value would be $1,599.2 million, or $24.29 per share.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including research and development and working capital.

• Pending use, proceeds may be invested in short- and intermediate-term, investment grade interest-bearing securities.